INBX
Inhibrx Biosciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
123.46
P/S
715.97
EV/EBITDA
-7.21
DCF Value
$0.61
FCF Yield
-13.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-91.0%
Operating Margin
-10386.5%
Net Margin
-10773.5%
ROE
-269.6%
ROA
-95.6%
ROIC
-117.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-32.8M | $-2.11 |
| FY 2025 | $1.3M | $-140.1M | $-9.04 |
| Q3 2025 | $0.00 | $-35.3M | $-2.28 |
| Q2 2025 | $1.3M | $-28.7M | $-1.85 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.51
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.